Efficacy, Adherence and Side Effects of PrEP for HIV-1 Prevention

Fang, Wanyi; Mphoyi, Bongani I.; Motake, Dineo R.; Liu, Jianxin; Li, Wenshuang; Mei, Fanghua; Lai, Shenghan; Wang, Jun

doi:10.5539/ijb.v11n4p80

Cited by 4 publications

(3 citation statements)

References 44 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effectiveness of PrEP for HIV prevention has been demonstrated in several studies including iPrEx (Pre-Exposure Initiative), the Partners PrEP study, the Bangkok Tenofovir study, Strand study, among others [7][8][9][10]. Protection levels varied from 44% -99% depending on the study and levels of adherence achieved [11]. Based on this, PrEP was recommended by the World Health Organization (WHO) for persons at substantial risk of HIV acquisition of which FSW fit the characterization [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Factors associated with retention on pre-exposure prophylaxis among female sex workers in Kigali, Rwanda

Mubezi,

Rwibasira,

Uwineza

et al. 2023

PLOS Glob Public Health

View full text Add to dashboard Cite

Pre-Exposure Prophylaxis (PrEP) is recommended as an additional HIV prevention measure for persons at substantial risk of HIV acquisition. Although uptake of PrEP among female sex workers (FSW) has increased, retention remains low, resulting in suboptimal benefits. This study aimed at determining PrEP retention rates and associated factors among FSW in Kigali, Rwanda. We retrospectively studied records of 309 FSW abstracted from five (5) health centers for the period between April-June 2020 and April-June 2021. PrEP retention was defined as presenting for a scheduled follow-up visit. We used Kaplan-Meier survival analysis to estimate survival probabilities at months 1,3,6,9, and 12 post-PrEP initiation and Cox regression to determine factors associated with 12-month PrEP retention. Data was analyzed using STATA (version 14.0). Out of 309 FSW whose records were reviewed, data for 268 (87%) were complete. One half (50%, n = 133) of the respondents were aged 25–34 years; slightly more than half (52%, n = 136) were single; nearly three-quarters (73%, n = 196) had completed primary school; majority (88%, n = 236) lived alone; while 69% (n = 184) had no formal employment besides sex work. PrEP dropout rates were 228, 65, 29, 49, and 36 per 100-persons years at months 1, 3, 6, 9 and 12 respectively, with 81%, 72%, 67%, 59% and 53% of FSW that started PrEP retained at these time periods. Multivariable Cox regression revealed that compared to FSW opposed to additional children, the desire to have two or more children (adjusted Hazard Ratio [aHR] = 1.654; 95% Confidential Interval [95%CI]: 1.008, 2.713); and using hormonal (aHR = 2.091, 95%CI: 1.181, 3.702) or no method of contraception other than condoms (aHR = 2.036, 95%CI: 1.006, 4.119) were factors positively associated with PrEP retention. Conversely, compared to consistent condom-use, not using (aHR = 0.329; 95%CI: 0.149, 0.726) or inconsistently using condoms (aHR = 0.413; 95%CI: 0.228, 0.749), and accessing PrEP from ultra-urban clinics (aHR = 0.290; 95%CI: 0.183, 0.458) compared to clinics in the outskirts of the city, were factors negatively associated with PrEP retention. The study found a continuous decline in PrEP retention among FSW with slightly more than half retained at 12 months. To improve outcomes, PrEP retention monitoring should target FSW enrolled in ultra-urban clinics and those not or inconsistently using condoms.

show abstract

Section: Introductionmentioning

confidence: 99%

Factors associated with retention on pre-exposure prophylaxis among female sex workers in Kigali, Rwanda

Mubezi,

Rwibasira,

Uwineza

et al. 2023

PLOS Glob Public Health

View full text Add to dashboard Cite

show abstract

“… 4 In African women, clinical trials evaluating daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (TDF/FTC) for pre-exposure prophylaxis demonstrated inconsistent results, most likely owing to varying adherence levels. 5 While an effective vaccine remains a major challenge, new HIV prevention strategies are urgently required. 6 …”

Section: Introductionmentioning

confidence: 99%

“…Insights from universal testing and treatment trials demonstrate that early treatment alone is not sufficient to reduce the number of new infections and achieve epidemic control, but that effective HIV prevention methods are also needed 4. In African women, clinical trials evaluating daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (TDF/FTC) for pre-exposure prophylaxis demonstrated inconsistent results, most likely owing to varying adherence levels 5. While an effective vaccine remains a major challenge, new HIV prevention strategies are urgently required 6…”

Section: Introductionmentioning

confidence: 99%

Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial

et al. 2020

View full text Add to dashboard Cite

IntroductionNew HIV prevention strategies are urgently required. The discovery of broadly neutralising antibodies (bNAbs) has provided the opportunity to evaluate passive immunisation as a potential prevention strategy and facilitate vaccine development. Since 2014, several bNAbs have been isolated from a clade C-infected South African donor, CAPRISA 256. One particular bNAb, CAP256-VRC26.25, was found to be extremely potent, with good coverage against clade C viruses, the dominant HIV clade in sub-Saharan Africa. Challenge studies in non-human primates demonstrated that this antibody was fully protective even at extremely low doses. This bNAb was subsequently structurally engineered and the clinical variant is now referred to as CAP256V2LS.Methods and analysisCAPRISA 012B is the second of three trials in the CAPRISA 012 bNAb trial programme. It is a first-in-human, phase I study to assess the safety and pharmacokinetics of CAP256V2LS. The study is divided into four groups. Group 1 is a dose escalation of CAP256V2LS administered intravenously to HIV-negative and HIV-positive women. Group 2 is a dose escalation of CAP256V2LS administered subcutaneously (SC), with and without the dispersing agent recombinant human hyaluronidase (rHuPH20) as single or repeat doses in HIV-negative women. Groups 3 and 4 are randomised placebo controlled to assess two (CAP256V2LS+VRC07-523LS; CAP256V2LS+PGT121) and three (CAP256V2LS+VRC07-523LS+PGT121) bNAb combinations administered SC to HIV-negative women. Safety will be assessed by the frequency of reactogenicity and adverse events related to the study product. Pharmacokinetic disposition of CAP256V2LS alone and in combination with VRC07-523LS and PGT121 will be assessed via dose subgroups and route of administration.Ethics and disseminationThe University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC) and the South African Health Products Regulatory Authority (SAHPRA) have granted regulatory approval (trial reference numbers: BREC00000857/2019 and SAHPRA 20200123). Trial results will be disseminated through conference presentations, peer-reviewed publications and the clinical trial registry.Trial registration numberPACTR202003767867253; Pre-results.

show abstract

Stability and bifurcation analysis of an HIV model with pre-exposure prophylaxis and treatment interventions

Chazuka,

Mudimu,

Mathebula

2024

Scientific African

View full text Add to dashboard Cite

Efficacy, Adherence and Side Effects of PrEP for HIV-1 Prevention

Cited by 4 publications

References 44 publications

Factors associated with retention on pre-exposure prophylaxis among female sex workers in Kigali, Rwanda

Factors associated with retention on pre-exposure prophylaxis among female sex workers in Kigali, Rwanda

Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial

Stability and bifurcation analysis of an HIV model with pre-exposure prophylaxis and treatment interventions

Contact Info

Product

Resources

About